Everyday HealthAdjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma

Presented at the virtual American Society of Clinical Oncology (ASCO) annual meeting, the findings from the S1404 clinical trial demonstrated that, although the PD-1 inhibitor pembrolizumab (Keytruda) came up short in both the intent-to-treat (ITT) population and PD-L1-positive subgroup, relapse-free survival (RFS) was significantly improved compared with those who received either ipilimumab (Yervoy) or high-dose […]

Dana-Farber Cancer InstituteImmunotherapy Combination Shows Benefit for Patients w. Advanced Melanoma, Phase 3 Trial Shows

The results of the trial, known as the RELATIVITY-047 study, were presented at the virtual ASCO Annual Meeting that took place June 4-8, 2021. The Dana-Farber Cancer Institute Investigators who co-led the study were thrilled to present that, despite PD-1 blocker nivolumab revolutionizing the treatment of patients with advanced melanoma, this fixed-dose combination of nivolumab […]

M35 Cancer-Fighting Foods That Have Researchers’ Attention

According to the American Institute for Cancer Research, a diet filled with a variety of vegetables, fruits, whole grains, beans, and other plant foods helps lower risk for many cancers, thanks to their bioactive compounds. Things like bergamottin. Isothiocyanates. Polyphenols. Continue reading to discover five foods that have the potential to fight cancer, including pancreatic, […]

HMP CommunicationsCosibelimab Safe, Clinically Active in Patients With mCSCC

In Study CK-301-101, the primary efficacy endpoint was objective response rate (complete + partial response, by independent central review), which was 47% (n = 15) in 32 metastatic cutaneous squamous cell carcinoma (mCSCC) patients evaluable for response, including three complete responses and 12 partial responses. The results from the study were presented at the ESMO […]